- Our World
- Our Business
- Life at Lupin
- Global Sites
Lupin’s 200+ strong Biotechnology Group has developed a robust pipeline of biosimilars addressing therapies like Oncology, Anti-Inflammatory, Anti-Virals, Rheumatoid Arthritis, Endocrinology, Diabetes, Ophthalmology and Women’s Health.
Over the last 8 years, the Company has gained deep insight in terms of product development, market intelligence regulatory and Intellectual Property.
Highlights for FY 2016
The Company is also making significant investments to augment its Biotech Manufacturing and R&D infrastructure. Lupin’s own fill finish facility is expected to be operational in FY 2017.